The FDA recently approved the use of Epidiolex (a plant-based formulation of CBD) to treat seizures for people 2 years of age and older with Dravet syndrome . Amotivational syndrome is a chronic psychiatric disorder characterized by a variety of and behavioral effects, other negative reactions to cannabis are sometimes found. .. Huntington's disease, Tourette's syndrome, Alzheimer's disease, epilepsy . Many effects of marijuana may be applicable to the management of ALS. Anticonvulsants and atypical antipsychotics are also used to treat PTSD. Twelve-month use of mental health services in the United States: results from the and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
other disorders and health epilepsy Cannabidiol manage mental
For both epilepsy and anxiety, there is more research available that shows some promise; a new medication made from cannabis for seizures caused by Lennox-Gastaut syndrome and Dravet syndrome has been approved by an advisory committee for the FDA, but does not have FDA approval. The participants were evaluated for symptom levels and IQ performance on standardized tests. There was insignificant improvement on cognitive function and symptom reduction, and nominal improvement on impulsivity and hyperactivity.
The researchers expressed concern that the participants did not follow instructions to avoid all other medications or alcohol use that could have affected the study results. The research authors stated that their results were inconclusive. This study showed poor cognitive function outcome for young adults who began using cannabis before the age of 16, including young people with an ADHD diagnosis.
When evaluated for working memory, verbal memory, decision-making and recall, these young users had poor performance on all points. They made more mistakes when asked to complete questions or tasks. Adverse Health Effects of Marijuana Use. Volkow, MD, and her colleagues, details the known health effects of marijuana use.
THC is a concern, as are other components of the plant, for health. Adverse effects include decreased cognitive abilities and exacerbated co-occurring mental health disorders and substance abuse.
Preclinical and clinical studies show CBD possesses a wide range of therapeutic properties, including antipsychotic, analgesic, neuroprotective, anticonvulsant, antiemetic, antioxidant, anti-inflammatory, antiarthritic, and antineoplastic properties see [ 11 , 12 , 16 — 19 ] for reviews. Pharmacology relevant to these actions is detailed below. The primary mechanism by which eCBs regulate synaptic function is retrograde signaling, wherein eCBs produced by depolarization of the postsynaptic neuron activate presynaptic CB 1 Rs, leading to inhibition of neurotransmitter release [ 23 ].
Interactions with the TRPV1 receptor, in particular, appear to be critical in regulating the extent to which eCB release leads to inhibition or facilitation of presynaptic neurotransmitter release [ 25 ]. TRPV1 receptors are also expressed in the brain, including the amygdala, periaqueductal grey, hippocampus, and other areas [ 26 , 27 ]. The eCB system regulates diverse physiological functions, including caloric energy balance and immune function [ 28 ].
The eCB system is also integral to regulation of emotional behavior, being essential to forms of synaptic plasticity that determine learning and response to emotionally salient, particularly highly aversive events [ 29 , 30 ]. Activation of CB 1 Rs produces anxiolytic effects in various models of unconditioned fear, relevant to multiple anxiety disorder symptom domains reviewed in [ 30 — 33 ]. Regarding conditioned fear, the effect of CB 1 R activation is complex: CB 1 R activation may enhance or reduce fear expression, depending on brain locus and the eCB ligand [ 34 ]; however, CB 1 R activation potently enhances fear extinction [ 35 ], and can prevent fear reconsolidation.
Genetic manipulations that impede CB 1 R activation are anxiogenic [ 35 ], and individuals with eCB system gene polymorphisms that reduce eCB tone—for example, FAAH gene polymorphisms—exhibit physiological, psychological, and neuroimaging features consistent with impaired fear regulation [ 36 ]. Reduction of AEA—CB 1 R signaling in the amygdala mediates the anxiogenic effects of corticotropin-releasing hormone [ 37 ], and CB 1 R activation is essential to negative feedback of the neuroendocrine stress response, and protects against the adverse effects of chronic stress [ 38 , 39 ].
Accordingly, CB 1 R activation has been suggested as a target for anxiolytic drug development [ 15 , 43 , 44 ]. In addition to dose-dependent activation of TRPV1 channels, the anxiogenic versus anxiolytic balance of CB 1 R agonists also depends on dynamic factors, including environmental stressors [ 33 , 49 ]. In preclinical studies, 5-HT 1A R agonists are anxiolytic in animal models of general anxiety [ 51 ], prevent the adverse effects of stress [ 52 ], and enhance fear extinction [ 53 ].
They are expressed on serotonergic neurons in the raphe, where they exert autoinhibitory function, and various other brain areas involved in fear and anxiety [ 54 , 55 ].
Mechanisms underlying the anxiolytic effects of 5-HT 1A R activation are complex, varying between both brain region, and pre- versus postsynaptic locus, and are not fully established [ 56 ]. Initial studies of CBD in these models showed conflicting results: When tested over a wide range of doses in further studies, the anxiolytic effects of CBD presented a bell-shaped dose—response curve, with anxiolytic effects observed at moderate but not higher doses [ 61 , 90 ].
All further studies of acute systemic CBD without prior stress showed anxiolytic effects or no effect [ 62 , 65 ], the latter study involving intracerebroventricular rather than the intraperitoneal route. No anxiogenic effects of acute systemic CBD dosing in models of general anxiety have yet been reported. As yet, few studies have examined chronic dosing effects of CBD in models of generalized anxiety. Anxiolytic effects in models used: Anxiolytic effects of CBD in models of generalized anxiety have been linked to specific receptor mechanisms and brain regions.
The midbrain dorsal periaqueductal gray DPAG is integral to anxiety, orchestrating autonomic and behavioral responses to threat [ 91 ], and DPAG stimulation in humans produces feelings of intense distress and dread [ 92 ]. The bed nucleus of the stria terminalis BNST serves as a principal output structure of the amygdaloid complex to coordinate sustained fear responses, relevant to anxiety [ 93 ].
In the prelimbic cortex, which drives expression of fear responses via connections with the amygdala [ 94 ], CBD had more complex effects: As noted, CBD has been found to have a bell-shaped response curve, with higher doses being ineffective.
Stress is an important contributor to anxiety disorders, and traumatic stress exposure is essential to the development of PTSD.
In a chronic study, systemic CBD prevented increased anxiety produced by chronic unpredictable stress, in addition to increasing hippocampal AEA; these anxiolytic effects depended upon CB 1 R activation and hippocampal neurogenesis, as demonstrated by genetic ablation techniques [ 81 ]. Finally, CBD, partially via CB 1 Rs, decreased defensive immobility and explosive escape caused by bicuculline-induced neuronal activation in the superior colliculus [ 89 ].
Several studies assessed CBD using contextual fear conditioning. Briefly, this paradigm involves pairing a neutral context, the conditioned stimulus CS , with an aversive unconditioned stimulus US , a mild foot shock. After repeated pairings, the subject learns that the CS predicts the US, and subsequent CS presentation elicits freezing and other physiological responses.
By contrast, CBD microinjection in the infralimbic cortex enhanced conditioned freezing [ 70 ]. Finally, El Batsh et al. In this study, CBD was administered prior to conditioning rather than prior to re-exposure as in acute studies, thus further directly comparable studies are required. CBD has also been shown to enhance extinction of contextually conditioned fear responses. Extinction training involves repeated CS exposure in the absence of the US, leading to the formation of a new memory that inhibits fear responses and a decline in freezing over subsequent training sessions.
Further studies showed CB 1 Rs in the infralimbic cortex may be involved in this effect [ 82 ]. CBD also blocked reconsolidation of aversive memories in rat [ 76 ].
Briefly, fear memories, when reactivated by re-exposure retrieval , enter into a labile state in which the memory trace may either be reconsolidated or extinguished [ 97 ], and this process may be pharmacologically modulated to achieve reconsolidation blockade or extinction. Overall, existing preclinical evidence strongly supports the potential of CBD as a treatment for anxiety disorders.
Activation of 5-HT 1A Rs appears to mediate anxiolytic and panicolytic effects, in addition to reducing conditioned fear expression, although CB 1 R activation may play a limited role. While CBD predominantly has acute anxiolytic effects, some species discrepancies are apparent. In addition, effects may be contingent on prior stress and vary according to brain region.
Further receptor-specific studies may elucidate the receptor specific basis of this distinct dose response profile. Further studies are also required to establish the efficacy of CBD when administered in chronic dosing, as relatively few relevant studies exist, with mixed results, including both anxiolytic and anxiogenic outcomes.
In particular, results show potential for the treatment of multiple PTSD symptom domains, including reducing arousal and avoidance, preventing the long-term adverse effects of stress, as well as enhancing the extinction and blocking the reconsolidation of persistent fear memories. The anxiolytic effects of CBD in humans were first demonstrated in the context of reversing the anxiogenic effects of THC. CBD reduced THC-induced anxiety when administered simultaneously with this agent, but had no effect on baseline anxiety when administered alone [ 99 , ].
Further studies using higher doses supported a lack of anxiolytic effects at baseline [ , ]. By contrast, CBD potently reduces experimentally induced anxiety or fear.
CBD reduced anxiety associated with a simulated public speaking test in healthy subjects, and in subjects with SAD, showing a comparable efficacy to ipsapirone a 5-HT 1A R agonist or diazepam [ 98 , ]. CBD also reduced the presumed anticipatory anxiety associated with undergoing a single-photon emission computed tomography SPECT imaging procedure, in both healthy and SAD subjects [ , ].
Finally, CBD enhanced extinction of fear memories in healthy volunteers: These rCBF changes were not correlated with anxiolytic effects [ ]. In a series of placebo-controlled studies involving 15 healthy volunteers, Fusar-Poli et al. Response activation is diminished in PTSD and other anxiety disorders, and increased activation predicts response to treatment [ ].
CBD produced no changes in predicted areas relative to placebo but reduced activation in the left insula, superior temporal gyrus, and transverse temporal gyrus. The fearful faces task activates the amygdala, and other medial temporal areas involved in emotion processing, and heightened amygdala response activation has been reported in anxiety disorders, including GAD and PTSD [ , ].
CBD attenuated blood-oxygen-level dependent activation in the left amygdala, and the anterior and posterior cingulate cortex in response to intensely fearful faces, and also reduced amplitude in skin conductance fluctuation, which was highly correlated with amygdala activation [ ]. Dynamic causal modeling analysis in this data set further showed CBD reduced forward functional connectivity between the amygdala and anterior cingulate cortex [ ].
Epidemiological studies of various neuropsychiatric disorders indicate that a higher CBD content in chronically consumed cannabis may protect against adverse effects of THC, including psychotic symptoms, drug cravings, memory loss, and hippocampal gray matter loss [ — ] reviewed in [ ]. As THC acutely induces anxiety, this pattern may also be evident for chronic anxiety symptoms. Two studies were identified, including an uncontrolled retrospective study in civilian patients with PTSD patients [ ], and a case study in a patient with severe sexual abuse-related PTSD [ ], which showed that chronic cannabis use significantly reduces PTSD symptoms; however, these studies did not include data on the THC: Thus, overall, no outcome data are currently available regarding the chronic effects of CBD in the treatment of anxiety symptoms, nor do any data exist regarding the potential protective effects of CBD on anxiety potentially induced by chronic THC use.
Evidence from human studies strongly supports the potential for CBD as a treatment for anxiety disorders: Limited results in healthy subjects also support the efficacy of CBD in acutely enhancing fear extinction, suggesting potential for the treatment of PTSD, or for enhancing cognitive behavioral therapy.
Further studies are also required to establish whether chronic, in addition to acute CBD dosing is anxiolytic in human. Human experimental findings support preclinical findings, and also suggest a lack of anxiogenic effects, minimal sedative effects, and an excellent safety profile. Overall, this review emphasizes the potential value and need for further study of CBD in the treatment of anxiety disorders.
Disclosure forms provided by the authors are available with the online version of this article. National Center for Biotechnology Information , U.
Journal List Neurotherapeutics v. Published online Sep 4. Blessing , 1 Maria M. Steenkamp , 1 Jorge Manzanares , 1, 2 and Charles R. Author information Copyright and License information Disclaimer. This article has been cited by other articles in PMC.
Abstract Cannabidiol CBD , a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders.
Electronic supplementary material The online version of this article doi: Anyone considering CBD oil should speak with a local healthcare provider. They can provide information about safe CBD sources and local laws surrounding usage. This is one of more than 80 active chemicals in marijuana. The new product was approved to treat seizures associated with two rare, severe forms of epilepsy in patients two years of age and older.
Many small-scale studies have looked into the safety of CBD in adults. They concluded that adults tend to tolerate a wide range of doses well. Researchers have found no significant side effects on the central nervous system , the vital signs, or mood, even among people who used high dosages. The most common side effect was tiredness. Also, some people reported diarrhea and changes in appetite or weight.
Concerning the product that the FDA approved to treat two types of epilepsy, researchers noticed following adverse effects in clinical trials:. The patient information leaflet notes that there is a risk of worsening depression or suicidal thoughts. It is important to monitor anyone who is using this drug for signs of mood change. Research suggests that a person taking the product is unlikely to form a dependency.
There is often a lack of evidence regarding the safety of new or alternative treatment options. Usually, researchers have not performed the full array of tests.
Anyone who is considering using CBD should talk to a qualified healthcare practitioner beforehand. When drugs do not have FDA approval, it can be difficult to know whether a product contains a safe or effective level of CBD.
Unapproved products may not have the properties or contents stated on the packaging. It is important to note that researchers have linked marijuana use during pregnancy to impairments in the fetal development of neurons. Regular use among teens is associated with issues concerning memory, behavior, and intelligence.
CBD-based products come in many forms. Some can be mixed into different foods or drinks or taken with a pipette or dropper. Others are available in capsules or as a thick paste to be massaged into the skin.
Some products are available as sprays to be administered under the tongue. Recommended dosages vary between individuals, and depend on factors such as body weight, the concentration of the product, and the health issue. Due to the lack of FDA regulation for most CBD products, seek advice from a medical professional before determining the best dosage. As regulation in the U. After discussing dosages and risks with a doctor, and researching regional local laws, it is important to compare different brands of CBD oil.
There is a selection of CBD products available for purchase online. CBD has been tested and approved for one specific use. Does this mean it is safe and will soon have approval for other uses? The research is emerging to support the use of CBD for numerous conditions, as well as looking closely at safety, side effects, and long-term effects. There are some valid concerns about long-term use that must be tested before CBD can be recommended for other diseases.
As one approach to pain management, it is seen as an alternative option to the addicting narcotics. The use of CBD oil might complement a medical approach to treating physical and mental diseases. It is worth discussing with your doctor. We picked linked items based on the quality of products, and list the pros and cons of each to help you determine which will work best for you.
We partner with some of the companies that sell these products, which means Healthline UK and our partners may receive a portion of revenues if you make a purchase using a link s above. Article last updated by Yvette Brazier on Fri 27 July All references are available in the References tab. Cannabidiol as a potential treatment for anxiety disorders.
Neurotherapeutics, 12 4 , — Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice [Abstract].
Journal of Alzheimer's Disease, 42 4 , 1,—1, Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55 6 , — An updated review of the research on the risks and harms associated to the use of marijuana. Highlights of prescribing information: Early phase in the development of cannabidiol as a treatment for addiction: Opioid relapse takes initial center stage.
Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes [Abstract].
Clinical Hemorheology and Microcirculation, 64 4 , — Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75 2 , — The legal status of cannabis marijuana and cannabidiol CBD under U. Cannabidiol reduces cigarette consumption in tobacco smokers: Addictive Behaviors, 38 9 , 2,—2, Marijuana on the brain: Innovations in Clinical Neuroscience, 15 1—2 , Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes.
The Journal of Clinical Investigation, 9 , 3,—3,
Everything you need to know about CBD oil
Nov 1, Information about the use of cannabis oil for epilepsy to gain seizure control. Guidance for other conditions is being drawn up the Royal College of Physicians with to THC can affect brain development, structure and mental health. to the general principles of investigation and management of epilepsy. Jun 27, Only certain patients have access to the cannabis-based oil under Texas' restrictive law available to him and thousands of other epilepsy patients across the state. . done to evaluate whether and how CBD oil can treat those illnesses. . them to attend the Mental Health Virtual Career Fair on Feb. Sep 27, CBD oil, a cannabis product, can be used to treat the symptoms of ADHD, have epilepsy and some people who experience anxiety who use CBD oil, abilities and exacerbated co-occurring mental health disorders and substance abuse. Dr. Volkow lists several health conditions that might be able to be.